Payment overview · 2025
General Payments
$112.22
2 reported records · 2 companies
Healthcare provider profile · identity verified
Ingrid Gonzalez, M.D
Allopathic & Osteopathic Physicians|General Practice · HORMIGUEROS, PR · NPI 1396939708
Verified facts
What the public records show
CMS Open Payments records show Ingrid Gonzalez, M.D received $112.22 in general payments during 2025 across 2 reported records.
Lilly USA, LLC accounted for 80.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 320 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $90.03 | 80.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.19 | 19.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $112.22 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $90.03 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
320 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 536 | 74 |
| Famotidine | Famotidine | 513 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 429 | 94 |
| Lisinopril | Lisinopril | 360 | 80 |
| Losartan Potassium | Losartan Potassium | 360 | 71 |
| Synthroid | Levothyroxine Sodium | 320 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 34 |
| Omeprazole | Omeprazole | 271 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 256 | 39 |
| Simvastatin | Simvastatin | 242 | 63 |
| Metformin Hcl | Metformin Hcl | 230 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 26 |
| Glimepiride | Glimepiride | 166 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 46 |
| Alendronate Sodium | Alendronate Sodium | 160 | 19 |
| Metformin Hcl Er | Metformin Hcl | 157 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 23 |
| Carvedilol | Carvedilol | 141 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 125 | 52 |
| Temazepam | Temazepam | 116 | 16 |
| Glipizide | Glipizide | 111 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 100 | 14 |
| Clonazepam | Clonazepam | 99 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 94 | 15 |
| Irbesartan | Irbesartan | 93 | 18 |
| Meloxicam | Meloxicam | 93 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 52 |
| Atenolol | Atenolol | 86 | 15 |
| Cilostazol | Cilostazol | 86 | suppressed |
| Allopurinol | Allopurinol | 81 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 81 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 24 |
| Furosemide | Furosemide | 76 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 15 |
| Finasteride | Finasteride | 75 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 13 |
| Nifedipine Er | Nifedipine | 68 | 13 |
| Prednisone | Prednisone | 66 | 22 |
| Glipizide Er | Glipizide | 64 | 13 |
| Levoxyl | Levothyroxine Sodium | 64 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 60 | 11 |
| Tradjenta | Linagliptin | 60 | suppressed |
| Humalog | Insulin Lispro | 59 | suppressed |
| Eliquis | Apixaban | 58 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | suppressed |
| Spironolactone | Spironolactone | 57 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Levetiracetam | Levetiracetam | 54 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 52 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 50 | 13 |
| Trazodone Hcl | Trazodone Hcl | 47 | 12 |
| Tramadol Hcl | Tramadol Hcl | 45 | 13 |
| Latanoprost | Latanoprost | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Jardiance | Empagliflozin | 40 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Alprazolam | Alprazolam | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 36 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Brilinta | Ticagrelor | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 25 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 24 | 14 |
| Levofloxacin | Levofloxacin | 24 | 22 |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Lumigan | Bimatoprost | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Desonide | Desonide | 19 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Cefprozil | Cefprozil | 18 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Advocate Syringes | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Advocate Syringes | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Advocate Syringes | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $112.22 · 2 records | Lilly USA, LLC | MOUNJARO, RINVOQ | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error